Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.01
-6.5%
$4.89
$3.42
$9.35
$225.42M1.632.56 million shs1.02 million shs
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
$1.13
-5.8%
$1.39
$1.09
$1.94
$54.53M0.48180,505 shs144,816 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$6.04
-5.2%
$9.49
$5.66
$27.50
$201.88MN/A233,969 shs473,142 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$2.10
-9.9%
$3.69
$2.08
$11.40
$203.40M-0.131.49 million shs1.44 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-6.53%-9.48%-20.28%-14.68%-44.38%
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
-5.83%-14.39%-16.30%-33.14%-15.36%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-5.18%-22.16%-46.31%-67.51%+603,999,900.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-9.87%-28.08%-42.15%-63.48%-65.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.277 of 5 stars
0.02.00.00.01.40.80.6
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
1.994 of 5 stars
3.33.00.00.00.61.71.3
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.0753 of 5 stars
3.50.00.00.02.61.70.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.8248 of 5 stars
3.33.00.04.10.63.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
2.50
Moderate Buy$3.00165.49% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.25516.72% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$18.38775.00% Upside

Current Analyst Ratings Breakdown

Latest IKNA, MBX, ACB, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/28/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
2/5/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Atb Cap Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.70$0.15 per share26.35$8.18 per share0.49
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
$659K82.75N/AN/A$3.52 per share0.32
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0580.229.11N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
-$68.17M-$1.01N/AN/AN/AN/A-36.88%-33.08%5/12/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.13N/AN/AN/AN/A-32.76%-31.33%5/12/2025 (Estimated)

Latest IKNA, MBX, ACB, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2025Q4 2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
3/11/2025Q4 2024
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
-$0.23-$0.18+$0.05-$0.19N/AN/A
2/5/2025Q3 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$0.09$0.06+$0.15$0.41$80.01 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
N/A
15.32
15.32
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
32.99
32.99

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
75.00%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
5.94%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
15.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
7048.26 million45.39 millionNot Optionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.42 millionN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.30 million72.11 millionNot Optionable

Recent News About These Companies

Oppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.01 -0.28 (-6.53%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$4.03 +0.02 (+0.60%)
As of 04/4/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Ikena Oncology stock logo

Ikena Oncology NASDAQ:IKNA

$1.12 -0.08 (-6.75%)
As of 04/4/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$6.04 -0.33 (-5.18%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$5.76 -0.28 (-4.62%)
As of 04/4/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$2.10 -0.23 (-9.87%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$2.20 +0.11 (+5.00%)
As of 04/4/2025 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.